Molding minds: clay therapy tested for schizophrenia recovery
NCT ID NCT07378150
First seen Jun 24, 2026 · Last updated Jul 29, 2026 · Updated 4 times
Summary
This study tests whether clay therapy can improve daily function and social performance in people with schizophrenia who are already on medication. Seventeen participants will take part in clay sessions, and researchers will measure changes in their ability to handle daily tasks and interact with others. It is a small, early-stage trial exploring art therapy as a possible add-on treatment.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- clay therapy (art therapy using clay)
- What this could lead to
- If it works, this could offer a low-cost, non-drug way to help people with schizophrenia improve their daily living and social skills.
- What could go wrong
- This is a very small study (17 people) with no control group, so results may not be reliable or generalizable. The therapy is added on top of standard medication, so any benefit may be modest.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
17 people
The number who actually took part.
- Started
-
Dec 2025
- Finished
-
Jan 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Having been diagnosed with schizophrenia, * Being aged 18 or over, * Having completed at least primary school education, * Having achieved treatment compliance, * Currently undergoing pharmacological treatment, * Being in remission, * Having attended the Community Mental Health Centre regularly over the past year, * Having agreed to participate in the study * Scoring 20 points or higher on the Mini Mental State Examination Exclusion Criteria: * Being under 18 years of age, * Not having an education, * Not having a diagnosis of schizophrenia, * Not adhering to treatment, * Not taking pharmacological treatment regularly, * Being in an acute attack/active phase, * Lacking insight
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizophrenia are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Kutahya Health Sciences University
Kütahya, Turkey (Türkiye)
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia